Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS USA.
Autophagy. 2022 Feb;18(2):459-461. doi: 10.1080/15548627.2021.2008693. Epub 2021 Dec 6.
SQSTM1/p62 (sequestosome 1) is a macroautophagy/autophagy receptor protein that is degraded by selective autophagy. Intracellular accumulation of SQSTM1 activates multiple cell survival signaling pathways including NFΚB/NF-κB (nuclear factor kappa B), MTOR (mechanistic target of rapamycin kinase) and NFE2L2/Nrf2 (nuclear factor, erythroid derived 2, like 2). Both SQSTM1 and NFE2L2 have been considered as oncogenic, and increased accumulation of SQSTM1 and NFE2L2 activation have been frequently observed in various cancers including hepatocellular carcinoma. In a recent study, we found that deletion of improved hepatic metabolic reprogramming and cell repopulation resulting in the attenuation of liver injury in mice with liver-specific deletion of and that have defective hepatic autophagy and persistent MTOR complex 1 (MTORC1) activation. To our surprise, hepatocytic deletion of promotes liver tumorigenesis in liver-specific and double-knockout mice. Overall, these findings reveal a complex interplay among autophagy, SQSTM1 and MTORC1 and their differential roles either as oncogenic or tumor suppressor in liver tumorigenesis depending on the disease stage and context.
SQSTM1/p62(自噬体相关蛋白 1)是一种选择性自噬的自噬受体蛋白。细胞内 SQSTM1 的积累会激活多种细胞存活信号通路,包括 NFΚB/NF-κB(核因子 kappa B)、MTOR(雷帕霉素靶蛋白激酶)和 NFE2L2/Nrf2(核因子,红细胞衍生 2 样 2)。SQSTM1 和 NFE2L2 都被认为是致癌的,在包括肝细胞癌在内的各种癌症中,经常观察到 SQSTM1 积累增加和 NFE2L2 激活。在最近的一项研究中,我们发现 缺失可改善肝脏代谢重编程和细胞再增殖,从而减轻肝脏特异性缺失 和 (其肝自噬缺陷和持续的 MTOR 复合物 1(MTORC1)激活)小鼠的肝损伤。令我们惊讶的是,肝实质细胞特异性缺失 会促进肝特异性 和 双敲除小鼠的肝肿瘤发生。总的来说,这些发现揭示了自噬、SQSTM1 和 MTORC1 之间的复杂相互作用,以及它们在肝肿瘤发生中作为致癌或肿瘤抑制因子的不同作用,这取决于疾病阶段和背景。